The societal impact of treatment with natalizumab of relapsing–remitting multiple sclerosis in Italian clinical practice: The Tysabri PharmacoEconomics (TyPE) Study
Multiple sclerosis progressively impairs patients’ ability to independently perform activities of daily living, reduces working capacity, and negatively affects social interactions and relationships, imposing a cost for the society. The aim of this study was to explore the impact on society of treat...
Main Authors: | B Polistena, F Spandonaro, R Capra, S Fantaccini, L Santoni, GB Zimatore, C Gasperini |
---|---|
Format: | Article |
Language: | English |
Published: |
AboutScience Srl
2019-06-01
|
Series: | Global & Regional Health Technology Assessment |
Online Access: | https://doi.org/10.1177/2284240319852956 |
Similar Items
-
Natalizumab (Tysabri) in multiple sclerosis patients
by: Viola Sacchi
Published: (2008-06-01) -
by: B Polistena, et al.
Published: (2019-06-01) -
Spanish consensus on the use of natalizumab (Tysabri®) – 2011
by: O. Fernández, et al.
Published: (2012-09-01) -
Spanish consensus on the use of natalizumab (Tysabri®)-2013
by: O. Fernández, et al.
Published: (2015-06-01) -
Natalizumab for relapsing-remitting multiple sclerosis
by: A. Horga, et al.
Published: (2011-01-01)